Verastem reports data from Phase 1 Study of VS-6063 (defactinib) in Japanese patients

06-03-2014 Business Wire HealthComments (0)


Verastem (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today presented preliminary data from an ongoing First-in-Asia Phase 1 trial of VS-6063 in Japanese patients with advanced solid tumors, including one patient with mesothelioma. The Phase 1 study assessed the safety and pharmacokinetics of single agent VS-6063. “We are encouraged that the safety and pharmacokinetic profile ob

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top